Aurinia Pharmaceuticals Inc $AUPH Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.7% during the 1st quarter, HoldingsChannel reports. The firm owned 757,435 shares of the biotechnology company’s stock after buying an additional 66,806 shares during the quarter. Janus Henderson Group PLC’s holdings in Aurinia Pharmaceuticals were worth $11,225,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Centaurus Financial Inc. acquired a new position in Aurinia Pharmaceuticals during the 1st quarter valued at about $904,000. Quantinno Capital Management LP increased its stake in shares of Aurinia Pharmaceuticals by 6.4% in the first quarter. Quantinno Capital Management LP now owns 87,614 shares of the biotechnology company’s stock valued at $1,298,000 after purchasing an additional 5,285 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $1,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $4,080,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Aurinia Pharmaceuticals by 4.6% during the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock valued at $24,658,000 after buying an additional 73,700 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ:AUPH opened at $14.93 on Wednesday. The company has a 50 day moving average of $15.93 and a 200-day moving average of $15.34. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.92 billion, a P/E ratio of 6.88 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a twelve month low of $10.34 and a twelve month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The business had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AUPH. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.33.

Insider Transactions at Aurinia Pharmaceuticals

In other news, CEO Kevin Tang purchased 343,620 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was purchased at an average cost of $15.28 per share, with a total value of $5,250,513.60. Following the purchase, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. This trade represents a 2.75% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 814,606 shares of company stock worth $12,455,129. Company insiders own 10.40% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.